Ipamorelin/CJC-1295 No DAC

Description

A powerful synergistic combination of growth hormone secretagogues. Ipamorelin provides selective GH release while CJC-1295 extends GH pulse duration for enhanced fat loss and recovery.

Overview

The combination of CJC-1295 (no DAC) and Ipamorelin produces synergistic increases in GH and IGF-1. Clinicians report improvements in fat loss, lean mass preservation, energy, and deep-wave sleep.

Mechanism of Action

CJC-1295 (no DAC) is a GHRH analogue that stimulates the pituitary to release endogenous GH and increases IGF-1. Ipamorelin is a GHRP. When administered together they have synergistic effects on GH with minimal impact on ghrelin, prolactin, ACTH, or cortisol.

Benefits

• •Enhanced fat loss
• •Muscle preservation
• •Improved sleep
• •Anti-aging benefits

Dosing Notes

Common protocols: 0.05-0.1 mL SQ at bedtime, 5 days/week, on an empty stomach 2-3 hours after the last meal.

Reported Side Effects

• •One myocardial infarction death reported in the CJC-1295 DAC Phase II trial, attributed by the attending physician to pre-existing asymptomatic coronary disease and considered unrelated to treatment.

Safety Notes

GH may be mitogenic; caution in patients with cancer or cancer risk. GH can mask hypothyroid symptoms - monitor thyroid panel. CJC-1295 and CJC-1295 w/DAC are banned by WADA.

Commonly Stacked With

Scientific References